Search Results

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

Boston Pharmaceuticals today announced the appointment of Margaret Koziel, M.D., as Chief Medical Officer (CMO). Juan Carlos Lopez-Talavera, M.D., Ph.D., who has served as acting CMO since December 2023, will move to an advisory role to Dr. Koziel and the Boston Pharmaceuticals team as the company advances its promising late-stage candidate BOS-580.

Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.

Boston Pharmaceuticals has today named Dr. Elias Zerhouni as the new Chair of its Board of Directors, with Stefan Meister standing down from the Board after six years to focus on his ongoing roles elsewhere.

Novo Holdings, a leading life science investor, announced that its Boston office has been named a 2024 Best Place to Work by the Boston Business Journal.

The closures follow Novartis’s acquisition of MorphoSys earlier this year.

Boston Pharmaceuticals today announced new Phase 2a data demonstrating the positive impact of BOS-580, an investigational, long-acting fibroblast growth factor 21 (FGF21) analogue, on the circulating lipidome and changes in the metabolomics advanced steatohepatitis fibrosis (MASEF) score in patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH).